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Abstract. Sesquiterpenes lactones (SLs) have been isolated from 
numerous genera of the family Asteraceae (compositae) and can 
also be found in other angiosperm families. They are described as 
the active constituents of a variety of medicinal plants used in 
traditional medicine for the treatment of inflammatory diseases. 
They are known to possess wide variety of biological and 
pharmacological activities such as antimicrobial, cytotoxic, anti-
inflammatory, antiviral, antibacterial, antifungal activities, effects 
on the central nervous and cardiovascular systems as well as 
allergenic potency. Their wide structural diversity and potential 
biological activities have made further interest among the chemists. 
The present chapter will be highlighted on the recent developments 
on the SLs and their diverse biological activities.  
 
1. Introduction 
 
      Sesquiterpene lactones (SLs) constitute a large and diverse group of 
biologically active plant chemicals that have been identified in several plant 
families such as Acanthaceae, Anacardiaceae, Apiaceae, Euphorbiaceae, 
Lauraceae, Magnoliaceae, Menispermaceae, Rutaceae, Winteraceae and 
Hepatideae etc [1]. However, the greatest numbers are found in the Compositae 
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(Asteraceae) family with over 3000 reported different structures [2]. 
Sesquiterpene lactones are a class of naturally occurring plant terpenoids that 
represent a diverse and unique class of natural products and are important 
constituent of essential oils, which are formed from head-to-tail condensation 
of three isoprene units and subsequent cyclization and oxidative 
transformation to produce a cis or trans-fused lactone. These secondary 
compounds are primarily classified on the basis of their carbocyclic skeletons 
into pseudoguainolides, guaianalides, germanocranolides, eudesmanolides, 
heliangolides and hyptocretenolides etc (Figure 1). 
 The suffix "olide" refers to the lactone function and is based on 
costunolide, a germanacranoride which is related to the ten-membered 
carbocyclic sesquiterpene, germacrone. However, SLs exhibit variety of other 
skeletal arrangements. An individual plant species generally produces one 
skeletal type of SLs concentrated primarily in the leaves and flower heads. 
The percentage of SLs per dry weight may vary from 0.01% to 8%. Losses of 
livestock intoxicated by plants containing SLs are well known. In fact, they 
have been shown to exhibit a wide range of biological activities. 
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Figure 1. Basic skeletons of sesquiterpenes lactones. 
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 An important usual feature of the SLs is the presence of a γ-lactone ring 
(closed towards either C-6 or C-8) containing in many cases, an α-methylene 
group. Among other modifications, the incorporation of hydroxyls or 
esterified hydroxyls and epoxide ring are common. A few SLs occur in 
glycoside form and some contain halogen or sulfur atoms [3].  
 Majority of SLs have shown cytotoxic activity (KB and P388 leukemia 
in vitro) and activity against in vivo P388 leukemia. Structure activity 
relationship studies showed that various cytotoxic SLs react with thiols, such 
as cystiene residues in the protien, by rapid Michael type of addition. These 
reactions are mediated chemically by α,β-unsaturated carbonyl system 
present in the SLs. These studies support the view that SLs inhibit                
tumor growth by selective alkylation of growth regulatory biological 
macromolecules such as key enzymes, which controls cell division, thereby 
inhibiting a variety of cellular functions, which directs the cell into apoptosis. 
Differences in activity between individual SLs may be explained by different 
number of alkylating structural elements. However, other factors, such as 
lipophilicity, molecular geometry, and chemical environment or the target 
sulfhydryl may also influence the activity of sesquitepenes lactones.  
 
O
O
HO
Costunolide (1)
O
O
O
O
HO
OH
O
Tagitinin A (2)
O
O
O
O
OH
O
Tagitinin C (3)
O
O
OHO
H
H
O
CH2OH
Cynaropicrin (4)
O
CH2OH
O
O
O
OH
Eupatoriopicrin (5)
O
O
O
HO
Parthenin (6)
O
OH
O
O
Helenalin (7)
O
O
O
O
O
H
Artemisinin (8)
O
O
CH2
O
O
O
HO
O
H
Vernodalin (9)
 
 
Figure 2. Structurally diverse sesquiterpenes lactones (SLs 1-9). 
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 Some of structurally diverse sesquiterpenes lactones have been shown in 
Figure 2 and 3. Distribution of different structural classes of sesquiterpene 
lactones have been depicted in Table 1. 
 
2. Biological activity of sesquiterpene lactones 
 
[A] Anticancer activity 
 
 In recent years, many researchers over the world have reported that 
sesquiterpenes lactones possess potential anticancer activity. Some of the 
important compounds of this class have been discussed below: 
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Figure 3. Structurally diverse sesquiterpenes lactones (10-21). 
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Table 1. Distribution of different structural classes of sesquiterpene lactones in the 
family-Compositae. 
 
Tribes 
(No. of genera)  
No. of genera with 
sesquiterpene 
lactones 
Type of lactones  
present  
Eupatorieae (50) 4 
Germacranolides 
Elemanolides  
Guaianolides  
Ambrosanolides  
Seco-Ambrosanolides 
Vernonieae (50) 4 
Germacranolides 
Elemanolides  
Guaianolides 
Astereceae (100) 1 
Germacranolides  
Guaianolides  
Elemanolides 
 
Inuleae (100) 5 
Guaianolides  
Xanthanolides  
Ambrosanolides  
Helenanolides  
Seco-Eudesmanolides  
Seco-Ambrosanolides  
Germacranolides 
 
Heliantheae (250) 24 
Elemanolides  
Guaianolides  
Eudesmanolides  
Xanthanolides  
Ambrosanolides  
Helenanolides  
Seco-Eudesmanolides  
Seco-Ambrosanolides  
Seco-Helenanolides 
 
Senecioneae (50) 4 
Germacranolides  
Xanthanolides  
Eremophilanolides  
Helenanolides  
Bakkenolides 
 
Anthemideae (50) 10 
Germacranolides  
Elemanolides  
Guaianolides  
Helenanolides  
Cadinanolides  
Chrymoranolides 
 
Arcototeae-
Calenduleae (50) 1 Guaianolides 
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Table 1. Continued 
 
Cynareae (50) 8 
Germacranolides  
Elemanolides  
Guaianolides  
Eudesmanolides 
Mutisieae (55) 1 Eudesmanolides 
Lactucae (75) 7 
Germanocranolides  
Eudesmanolides  
Guaianolides 
 
 
I. Costunolide 
 
 Costunolide (1, Figure 2) is an active component from the crude extract of 
Saussurea lappa roots, a traditional Chinese medicinal herb [3]. The anticancer 
property of costunolide was first reported in a rat intestinal carcinogenesis model 
induced by azoxymethane and supported by a subsequent study using a DMBA 
induced hamster buccal pouch carcinogenesis model [4]. Following these two      
in vivo experiments, considerable efforts have been devoted to understad the 
mechanism responsible for the anti-cancer activity of costunolide. First, 
costunolide is a potent apoptotic inducer in cancer cells, via multiple 
pathways. It has been reported that costunolide readily depletes intracellular 
GSH and disrupts the cellular redox balance [5]. It triggers an intracellular 
reactive oxygen species (ROS) burst which leads to mitochondrial 
dysfunction: loss of mitochondrial membrane potential, onset of mitochondrial 
membrane transition, and release of mitochondrial pro-apoptotic proteins [6].  
 The apoptosis-inducing activity of costunolide was found to be closely 
associated with Bcl-2, based on observations that costunolide treatment 
decreased the anti-apoptotic Bcl-2 protein expression [7], while over expression 
of Bcl-2 protein attenuated costunolide-induced apoptosis [12]. Second, 
costunolide suppresses NF-kB activation via prevention of IkB phosphorylation 
[8], a process also responsible for the strong anti-inflammatory activity of 
costunolide [9]. Third, costunolide is capable of promoting leukemia cell 
differentiation [10], inhibiting endothelial cells angiogenesis [11], and 
disrupting nuclear microtubule architecture in cancer cells [12]. 
 
II. Parthenolide 
 
 Parthenolide (10, Figure 3), is the major SL responsible for bioactivity of 
feverfew (Tanacetum parthenium), a traditional herb plant which has been 
used for the treatment of fever, migraine and arthritis for centuries [13]. One 
well-explored bioactivity of parthenolide is its potent anti-inflammatory 
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effect, which is mainly achieved through its strong inhibitory effect on            
NF-kB activation. It has been well established that parthenolide acts on 
multiple steps along the NF-kB signaling pathway [14]. By suppressing     
NF-kB parthenolide inhibits a group of NF-kB regulated pro-inflammatory 
cytokines, such as interleukins and prostaglandins [15]. The anticancer 
activity of parthenolide has been pursued in a number of laboratories. A large 
number of studies have been undertaken to investigate the mechanism of 
action of parthenolide at molecular levels in the different phases of 
carcinogenesis. The data were obtained using different tumor cell systems. 
Parthenolide induced apoptosis in pre-B acute lymphoblastic leukemia lines, 
including cells carrying chromosomal translocations [16]. Parthenolide 
induced rapid apoptotic cell death distinguished by loss of nuclear DNA, 
externalization of cell membrane phosphatidyl-serine, and depolarization of 
mitochondrial membranes at concentrations ranging from 5 to 100 μM. Steele 
et al. investigated the in vitro actions of parthenolide on cells isolated from 
patients with chronic lymphocytic leukemia. Brief exposure to the 
sesquiterpene lactone (one to three hours) was sufficient to induce caspase 
activation and commitment to cell death. The mechanism of cell killing was 
via parthenolide induced generation of ROS, resulting in turn in a pro-
apoptotic Bax conformational change, release of mitochondrial cytochrome C 
and caspase activation. Other studies also demonstrated that parthenolide-
mediated apoptosis correlated well with ROS generation. Parthenolide 
strongly induced apoptosis in four multiple myeloma cell lines, although 
there are considerable differences in susceptibility to the sesquiterpene 
lactone. KMM-1 and MM1S sensitive to parthenolide possess less catalase 
activity than the less sensitive KMS-5 and NCI-H929 cells. These findings 
indicate that parthenolide-induced apoptosis in multiple myeloma cells             
depend on increased ROS and that intracellular catalase activity is a crucial 
determinant of their sensitivity to parthenolide. Chen et al. also reported the 
anti-proliferative and apoptosis-inducing effects of parthenolide on           
human multiple myeloma cells, mediated by an enhancement of caspase-3 
activity [17]. 
 
III. Helenalin 
 
 Helenalin (7, Figure 2) is another SL, from Arnica species, which has 
been reported to possess cytotoxicity and anti-cancer activity [18]. Earlier 
studies demonstrated its potent activity to inhibit nucleic acid and protein 
synthesis [19]. Similiar to other anticancer SLs, mechanism of action mainly 
involve: (i) thiol depletion, (ii) inhibition of NF-kB, and (iii) induction         
of apoptosis [20]. These prominent bioactivities make helenalin another 
potential anti-cancer agent. 
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IV. Artemisinin and its derivatives 
 
 Given the high accumulation of iron in cancer cells, researchers Henry 
Lai and Narendra Singh became interested in possible artemisinin (8, Figure 2) 
activity against malignant cells and have used artemisinin against numerous 
cancer cells in vitro [21]. There are a number of properties shared by cancer 
cells that favor the selective toxicity of artemisinin against cancer cell lines 
and against cancer in vivo. In addition to their high rates of iron flux via 
transferrin receptors when compared to normal cells, cancer cells are also 
particularly sensitive to oxygen radicals. Artemisinin becomes cytotoxic in 
the presence of ferrous ion. Since iron influx is naturally high in cancer cells, 
artemisinin and its analogs can selectively kill cancer cells in vivo [22]. 
Furthermore, it is possible to increase or enhance iron flux in cancer cells by 
supplying conditions that lead to increased intracellular iron concentrations. 
However, intact in vivo systems do not need holotransferrin, since the body 
provides all the necessary iron transport proteins. In recent years, in order to 
search for potential anticancer agents many researchers have directed their 
efforts in synthesizing various kinds of artemisinin dimers, trimers, tetramers 
wherein several of which have shown potential anticancer activity and are in 
the various phases of clinical trials [23]. 
 
[B] Anti-inflammatory activity 
 
 Sesquiterpenes lactones have displayed potential anti-inflammatory 
activity through NF-kB pathway. Since NF-kB plays a central role in most 
disease processes, and since it can regulate the expression of many key genes 
involved in inflammatory as well as in a variety of human cancers [24],               
NF-kB represents a relevant and promising target for the development of new 
chemopreventive and chemotherapeutic agents. Some of the important SLs 
have displayed anti-inflammatory activity are as follows:  
 
I. Costunolide 
 
 Costunolide (1, Fig. 2) is a closely related sesquiterpene lactone analogue 
of parthenolide present in several plants such as Magnolia grandiflora, 
Tanacetum parthenium. Koo et al. showed that costunolide also dose-
dependently inhibited LPS-induced NF-kB activation. In this assay system, 
costunolide even exhibited more potent inhibitory activity than parthenolide. 
Detailed mechanism studies revealed that, similar to parthenolide, 
costunolide also significantly inhibited the degradation of IkB-α and IkB-β. 
In addition, costunolide also inhibited the phosphorylation of IkB-α. These 
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accumulative results indicate that costunolide inhibits NF-kB activation by 
preventing the phosphorylation of IkB, and therefore, sequestering the 
complex in an inactive form [8]. 
 
II. Parthenolide 
 
 Parthenolide (10, Figure 3) is a sesquiterpene lactone present in several 
medicinal plants that have been used in folk medicine for their anti-
inflammatory and analgesic properties. Several in vitro studies have shown 
that a great part of the anti-inflammatory action of this compound appears 
to be related to its ability to inhibit the NF-kB pathway. In vitro studies 
have proven that the sesquiterpene lactone parthenolide does not interfere 
with the generation of oxygen radicals [25], whereas it specifically inhibits 
activation of the NF-kB pathway by targeting IKK [26] and/or preventing 
the degradation of IkB-α and IkB-β [25]. Furthermore, parthenolide has 
recently been reported to exert beneficial effects during endotoxic shock in 
rats through inhibition of NF-kB DNA binding in the lung [27]. These 
effects of parthenolide may also accounts for its inhibition of pro-
inflammatory mediator genes, such as the gene for the inducible nitric 
oxide synthase after endotoxin stimulation in rat smooth muscle cells [28] 
and the gene for IL-8 in immune-stimulated human respiratory epithelial 
cells [29]. In addition, parthenolide has also been demonstrated to protect 
against myocardial ischemia and reperfusion injury in the rat by selective 
inhibition of IKK activation and IkBα degradation [30]. 
 
III. Helenalin 
 
 Since different types of sesquiterpene lactones showed inhibition of            
NF-kB activation at similar concentrations, this effect seems to be 
characteristic for many of the sesquiterpene lactones with an exomethylene 
group like parthenolide and costunolide. Exomethylene groups of α,β-
unsaturated carbonyl compounds can react by Michael type addition to 
sulfhydryl groups of cysteine residues in the DNA binding domain of the NF-kB 
subunit [31]. Recently, Lyu et al. provided evidence that a sesquiterpene 
lactone, helenalin (7, Fig. 2), containing two functional groups, namely α,β-
unsaturated carbonyl group and α-methylene-δ-lactone ring, exerts its effect 
by direct alkylation of the p65 subunit of NF-kB without inhibition of IkB 
degradation [32]. In vitro studies also demonstrated that helenalin selectively 
modifies the p-65 subunit of NF-kB at the nuclear level, therefore inhibiting 
its DNA binding [33]. However, costunolide differs from helenalin in a 
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number of functional groups and inhibits degradation of IkB by inhibiting 
phosphorylation of IkB. Therefore, another functional group other than the 
exomethylene group and the molecular geometry of sesquiterpene lactone 
compounds appear to be important factors to determine the mode of NF-kB 
inhibition. However, the epoxide group in parthenolide is not likely important 
because parthenolide is at least less effective to inhibit both NF-kB activation 
and NO production.    
 
[C] Anti-malarial activity 
 
I. Artemisinin and its derivatives 
 
 In 1972, a group of Chinese researchers isolated a new anti-malarial drug 
(+)- artemisinin (8, Figure 4), a sesquiterpene lactone of the amorphene           
sub-group of cadinene from the hexane extract of a traditional Chinese 
medicinal plant Artemesia annua (Asteraceae) - a plant which has been used 
for the treatment of fever and malaria since ancient times [23]. Artemisinin is 
a sesquiterpene lactone containing an endoperoxide linkage in it. This highly 
oxygenated sesquiterpene lactone peroxide, unlike most other anti-malarials, 
lacks nitrogen containing heterocyclic ring systems and was found to be 
superior plasmocidal and blood schizontocidal agent to conventional anti-
malarial drugs, such as chloroquine, quinine etc against malaria strains, 
without obvious adverse effects in patients.       
 Artemisinin is active at nanomolar concentrations in vitro both against 
chloroquine sensitive and resistant P. falciparum strains. However, the practical 
values of artemisinin, nevertheless, are impaired (i) poor solubility either in oil or 
water; (ii) high rate of parasite recrudescence after treatment; (iii) short-plasma 
half life (3-5h) and poor oral activity. However, a low level of resistance has  
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Figure 4. Structure of artemisinin and its analogs. 
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recently been observed using artemisinin, which disappeared as soon as the           
drug-selection pressure has been withdrawn. However, artemisinin with an 
endoperoxide linkage is a sensitive molecule for large scale derivatization. 
Fortunately, it was found that the carbonyl group of artemisinin 8, can be easily 
reduced to dihydroartemisinin 22 in high yields using sodium borohydride, which 
has in turn led to the preparation of a series of semi-synthetic first-generation 
analogues included oil soluble artemether 23, arteether 24, water soluble sodium 
artesunate 25, and sodium artelinate 26.  
 These three analogs become very potent anti-malarial drugs effective against 
chloroquine-resistant strains of P. falciparum. Artemether 23 has been included 
in the WHO lists of Essential Drugs for the treatment of severe MDR malaria. In 
this family, the Walter Reed Institute of research has patented a stable, water-
soluble derivative called artelinic acid 26 which is now being tested in animals.  
A key advantage of these endoperoxides containing anti-malarial agents, which 
have been used for nearly two decades, is the absence of drug resistance. It has 
been realized through the structure-activity relationship (SAR) of artemisinins 
that mainly endoperoxide affects the antimalarial activity. In order to increase 
antimalarial potency of these molecules, researchers around the world become 
interested to synthesize artemisinin dimers, trimers and tetramers in recent years. 
Many of them have shown promising antimalarial activity than artemisinin and 
their first generation analogs. 
 
II. Miscellaneous antimalarials  
 
 Antimalarial activity of sesquiterpenes lactones from Neurolena lobata has 
been documented (Figure 5) [34]. Germacranolide sesquiterpenes lactones like 
neurolenin B (17, IC50 = 0.62 μM) more potent than furanoheliangolides lobatin 
B (IC50 = 16.51 μM). Among the germacranolides, the shift of the double bond 
from the 2,3-position (neurolenin B) into the 3,4-position (lobatin A) led to 
dramatic decrease in the activity suggesting that one of the structural 
requirements is the presence of α/β-unsaturated keto function. Additionally, a 
free hydroxyl group at C-8 increased the antiplasmodial activity, while a free 
hydroxyl group at C-9 decreased the activity. 
 Goffin et al. investigated the antiplasmodial properties of Tithonia 
diversifolia against three strains of P. falciparum, and sesquiterpene lactone (Fig. 
5/Fig 3) Tagitinin C (3) was found to be active against FCA strain (IC50 = 0.33 μg/mL) [35]. Jenett-Siems et al. reported four sesquiterpenes, vernodalol (18),                
11β,13-dihydrovernodalin 11β,13-dihydrovernolide (19) and 11β,13,17,18-
tetrahydrovernolide from Vernonia colorata. Among these, vernodalol (18) and 
11β,13-dihydrovernodalin (19) exhibited the strongest antiplasmodial activity 
(IC50 = 4.8 and 1.1 μg/mL) respectively). Among the sesquiterpene lactones 
obtained from Artemisia afra, 1-desoxy-1α-peroxy-rupicolin A-8-O-acetate  
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Figure 5. Structures of some of anti-malarials sesquiterpene lactones. 
 
(20), 1β,4β-dihydroxy-bishopsolicepolide and rupicolin A-8-O-acetate (20) 
possessed in-vitro antiplasmodial activity (IC50 = 10.8-17.5 μg/mL) [36]. 
Passreiter et al. have isolated sesquiterpene lactones of the pseudoguaianolide 
type from Arnica Montana, helenalin (7), dihydrohelenalin and their acetates 
showing activities against P. falciparum in vitro (IC50 = 0.23 to 7.41 μM) [37]. 
Inhibitory effect upon the growth of P. falciparum has been reported                        
for sesquiterpene lactones (27) and (28) isolated from Camchaya calcarea               
(IC50 = 1.2 and 0.3 μg/mL) respectively [38]. 
 
[D] Antiviral activity 
 
 In spite of an effective and safe vaccine therapy against hepatitis B virus 
(HBV), viral infection by HBV caused a global health problem in the world, 
especially the third world. Moreover, because direct antiviral therapy against 
HBV infection is not yet perfectly developed, it is important to discover the 
lead compounds for novel anti-HBV agents from the potential library. 
Recently, there was a report about anti-HBV activity of artemisinin (8)                
and artesunate (25) based on the screening by using HBV-transferred                  
HepG2 2.2.15 cell [39], which is derived from hepatoblastoma HepG2 cell 
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[40]. This screening method is a useful in vitro model for evaluation of novel 
anti-HBV drugs, as well as to study several steps of the HBV biology [41]. 
Artemisinin (8), artesunate (25), and a variety of purified compounds from 
traditional Chinese medicine remedy were investigated by measuring the 
release of surface protein (HBsAg) and HBV-DNA after drug exposure 
(0.01-100 μM) for 21 days [39]. As a result, artesunate (25) strongly inhibited 
the HAsAg secretion with an IC50 of 2.3 μM and IC90 of 16 μM, respectively, 
whereas artemisinin (8) had a mild inhibition activity. To evaluate an 
enhancement in viron production, the amount of the HBV-DNA release to the 
HepG2 2.2.15 culture medium during different treatments was measured, and 
it was significantly reduced. In addition, it was discovered that, for artesunate 
(25), toxicity in host cell was shown in drug concentration of 20 μM and 
therapeutical index (TI) calculated from IC50 of HBV-DNA release was 40. 
When comparing to TI value (500) of lamivudine as positive control, the 
value of artesunate (25) is quite low, but reasonable value for further 
investigation. Finally, artesunate (25) was tried in combination treatment with 
lamivudine. When both compounds were administered together in 
concentration of 20 nM each, no toxicity was observed, but a synergic 
inhibitory effect in HBsAg release was found. It means that it is possible to 
be potential antiviral agent against infection of lamivudine-resistance                 
HBV strains, frequent problem in clinical treatment [42]. This result was 
quite similar to potency previously reported for human cytomegaloviruses 
[39]. 
 Anti-viral activity of various sesquiterpene lactones was reported by 
Hsieh and their coworkers against hepatitis C virus (Fig. 6) [43]. They have 
tested a series of 10 compounds such as parthenolide (10, EC50 = 2.21 μM), 
costunolide (1, EC50 = 2.69 μM), dehydrocostus lactone (11, EC50 = 3.08 μM), Helenalin (7, EC50 = 1.25 μM), alantolactone (14, EC50 = 2.03 μM), 
Epoxy-dihydrosantonin (15, EC50 = >10 μM), artemisinin, and two other 
conjugated lactones. Wherein they found the best anti-HCV activity was 
shown by helenalin. They have further derivatized a series of parthenolide 
analogs 29 wherein they found that best activity was realized while putting a 
piperidine moiety (R = piperidine, EC50 = 1.64 μM). 
 
[E] Antibacterial activity 
 
 There has been an overwhelming amount of evidence indicating that 
certain SLs are effective in exerting antibacterial activity. Rabe et al. showed 
that Vernonia colorata, a member of the Compositae found in west,              
central and South Africa possess SLs with antibacterial activity primarily 
against Gram-positive species and lower activity towards Gram-negative                
species [44]. The SLs vernodalin (30), vernolide (12) (Fig. 7) and 11β,13-
dihydroovernolide were isolated and screened against Staphylococcu aureus  
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Figure 6. Antiviral sesquiterpene lactones. 
 
and Bacillus subtilis (Gram-positive species) and Escherichia coli and 
Klebsiella pneumoniae (Gram-negative species). 
 11β,13-Dihydroovernolide is a novel SLs in that it has never been isolated 
from a Vernonia species before. All three of the compounds screened had very 
low inhibitory action against the Gram-negative bacteria. However, S. aureus and 
B. subtilis showed the most sensitivity towards all of the SLs screened. It needs to 
be noted, however, that although 11β,13-dihydrovernolide is a novel SL, it had 
the lowest activity against the Gram-positive species compared to vernolide and 
vernodalin which had MIC values of 0.1-0.5 mg/mL.  
 Taylor and Towers isolated, characterised and screened three SLs 
belonging to the pseudoguaianolides class of SLs from Centipeda minima, a 
member of the Compositae [45]. This plant is used throughout Southeast Asia 
to treat colds, coughs, and sinus infections. Three SLs, 6-O-methylacrylylplenolin 
(31), 6-O-angeloylplenolin (32), and 6-O-isobutyroylplenolin (33) (Figure 8) 
were isolated, with 6-O-methylacrylylplenolin being novel, and were then 
screened for antibacterial activity against B. subtilis and S. aureus. All three of the 
SLs screened had significant activity against the bacteria with 6-O-
isobutyroylplenolin being the most bioactive. Both 6-O-isobutyroylplenolin and 
6-O-methylacrylylplenolin exhibited MIC value of 150 μg/mL against B. subtilis. 
6-O-Angeloylplenolin was less active with a MIC of 300 μg/mL. All three 
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Figure 7. Antibacterial sesquiterpenes lactones (30, 12). 
 
SLs showed activity against both methicillin-resistant and methicillin-
sensitive strains of S. aureus. Both 6-O-isobutyroylplenolin and 6-O-
methylacrylylplenolin had a MIC of 300 μg/mL against methicillin-resistant 
S. aureus, while 6-O-angeloylplenolin was less active with a MIC of 600 
μg/mL against this strain. With respect to the methicillin-sensitive strain of  
S. aureus, 6-O-methylacrylylplenolin and 6-O-angeloylplenolin had MIC 
values of 75 μg/mL while 6-O-isobutyroylplenolin had a MIC of 38 μg/mL 
indicating that this SL is more bioactive against methicillin-sensitive                
S. aureus than the other SLs screened.  
 Further amplifying the possibility for the use of SLs found in plant oils, 
Wang and coworkers recently discovered four new SLs in a plant species known 
as Ligulariopsis shichuana, which is a new genus of the Compositae [46]. The 
four SLs isolated and characterised were: (a) 3β-acetoxy-9β-angeloyloxy-1β, 
10β-epoxy-8α-hydroxyeremophil-7(11)-en-8β-(12)-olide (34); (b) 3β-senecioyl-
oxy-1β,10β-epoxy-8α-hydroxyeremophil-7(11)-en-8β-(12)-olide (35); (c) 6β-
angeloyloxy-8α-hydroxyeremophil-1(10),7(11)-dien-8β-(12)-olide (36); and (d) 
1-oxo-6β-senecioyloxy-8α-hydroxyeremophil-7(11),9(10)-dien-β-(12)-olide (37)  
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Figure 8. Antibacterial sesquiterpene lactones (31-33). 
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Figure 9. Antibacterial sesquiterpenes lactones (34-37). 
 
(Fig. 9). Only compounds 34 and 35 were screened for their antibacterial activity. 
Compound 34 showed moderate activity towards both the Gram-positive and 
Gram-negative species B. subtilis and E. coli, respectively. Compound 35, while 
exhibiting moderate activity towards E. coli, showed much stronger activity 
against B. subtilis at MIC concentrations up to 100 μg/mL.    
 Finally, there have been reports that other SLs, such as helenalin 7, showed 
inhibitory action against Mycobacterium tuberculosis as well as activity against 
Corynebacterium diptheriae [47]. Helenalin 7, a mixture of alantolactone 14 and 
isoalantolactone 38, is derived from the plant species Inula helenium (Fig. 10). 
Helenalin 7 has primarily been utilised as an antiseptic for the urinary tract [47]. 
However, helenalin 7 was also shown to inhibit both Gram-positive and Gram-
negative bacterial growth, with the former showing more sensitivity [48]. As one 
can see, there is certain hope for those essential oils containing SLs in 
therapeutics. The preclinical data implicates that SLs are effective in reducing 
bacterial growth which gives strength to the idea that SLs could be potentially 
used in the medical treatment of both Grampositive and Gram-negative bacterial 
infections.    
 
O
O
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O
O
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Figure 10. Antibacterial sesquiterpene lactones (14, 38). 
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[F] Antifungal activity              
 
 There certainly exists a vast amount of empirical data supporting that 
certain SLs found in essential oils have the potential to act as antibacterial 
agents. It also needs to be shown that certain SLs also possess antifungal 
activities. The following section will focus on studies implicating the SLs for 
probable use as antifungal agents. 
 Calera et al. isolated, characterised, and screened two bioactive SLs from 
the roots of yellow flowered perennial herb Ratibida mexicana. This plant is 
found primarily along the Sierra Madre Occidental in the northwestern part of 
Mexico [49]. Indian tribes find that the roots are useful in alleviating 
headaches, colds and rheumatism. The two SLs isolated from this plant are 
isoallolantolactone (38) and elema-1,3,11-trien-8,12-olide (39) (Fig. 11).     
The in vitro antifungal screen revealed that both SLs inhibited the radial 
growth of Helminthosporium with the MIC being 650 μg/mL for both SLs. 
Pythium growth was far more sensitive to isoallolantolactone (38) with a 
MIC of 125 μg/mL. Fusarium was also screened for sensitivity against 
isoallolantolactone (38) and elema-1,3,11-trien-8,12-olide, with again 
isoallolantolactone (39) showing the most bioactivity by inhibiting 45% of 
radial growth at 200 μg/mL for this particular fungus.    
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O
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Figure 11. Antifungal activity of sesquiterpene lactones (38, 39). 
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Figure 12. Antifungal activity of sesquiterpene lactones (40-41). 
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 Two new eudesmanolides were isolated from the aerial parts of Centaurea 
thessala spp. drakiensis and C. attica spp. attica, plants which are primarily used 
in folk medicine in the Mediterranean region [50]. The two novel eudesmanolides 
isolated were 8α-hydroxy-4-epi-sonchucarpolide (40) and the 8α-(4-acetoxy-3-
hydroxy-2-methylenebutanoyloxy) derivative (41) of the 8α-hydroxy-4-epi-
sonchucarpolide, also known as 40-acetoxymalacitanolide (Fig. 12). 
 A variety of fungal species showed sensitivity towards 8α-hydroxy-4-
epi-sonchucarpolide (40) and 40-acetoxymalacitanolide (41) [50]. 8α-
Hydroxy-4-epi-sonchucarpolide 40, when compared to 40-
acetoxymalacitanolide 41, showed higher activity against all the fungal 
species screened, with the exception of one species. The MIC values for            
8α-hydroxy-4-epi-sonchucarpolide 40 were considerably lower indicating 
that sensitivity is much higher for this compound. The exception was for 
Cladosporium cladosporioides; this species showed higher sensitivity 
towards 40-acetoxymalacitanolide, with a MIC value of 0.06 μg/mL while 
the MIC value for 8α-hydroxy-4-epi-sonchucarpolide was 0.5 μg/mL.                 
In addition, both SLs had indentical MICs against Penicillium funiculosum, 
showing no disparity between these two SLs in their inhibitory action against 
this particular species. The authors of this paper speculated that the 
differences in activity between these two SLs could be attributed to the 
different skeletal types and functional groups present on the compounds. 
Finally, it needs to be mentioned that both SLs, possessed greater antifungal 
activity that miconazole, a commercial fungicide used as the positive control. 
 
3. Structural-activity relationships (sar) of sesquiterpene 
lactones         
 
 It is generally believed that the bioactivity of SLs is mediated                      
by alkylation of nucleophiles through their α, β- or α, β, γ-unsaturated           
carbonyl structures, such as α-methylene-γ-lactones or α,β-unsaturated 
cyclopentenones. These structure elements react with nucleophiles, especially 
the cysteine sulfhydryl groups by Michael-type addition. Therefore, it is 
widely accepted that thiol groups such as cysteine residues in proteins, as 
well as the free intracellular GSH, serve as the major targets of SLs.                      
In essence, the interaction between SLs and protein thiol groups or GSH 
leads to reduction of enzyme activity or causes the disruption of GSH 
metabolism and vitally important intracellular cell redox balance.  
 The relationship between chemical structure and bioactivity of SLs has 
been studied in several systems, especially with regards to cytotoxicity, anti-
inflammatory and antitumor activity. It is believed that the exo-methylene 
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group on the lactone is essential for cytotoxicity because structural 
modifications such as saturation or addition to the methylene group resulted 
in the loss of cytotoxicity and tumor inhibition. However, it has also been 
shown that the factor responsible for the cytotoxicity of SLs might be the 
presence of the O=C-C=CH2 system, regardless of lactone or cyclopentenone. 
It was latter demonstrated that the presence of additional alkylating groups 
greatly enhanced the cytotoxicity of SLs. Furthermore, it was established that 
the α-methylene-γ-lactones and α,β-unsaturated cyclopentenone ring (or α-
epoxycyclopentenone) present in SLs essential for their in vivo anti-tumor 
activity. It has been confirmed through various published reports that              
the various kinds of biological activities displayed by SLs is due to presence 
of either α-methylene-γ-lactones and α,β-unsaturated cyclopentenone ring.              
In summary, the differences in activity among individual SLs may be 
explained by differences in the number of alkylating elements, lipophilicity, 
molecular geometry, and the chemical environment of the target sulfhydryl 
group.  
 
O
O
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Figure 13. General structure of sesquiterpene lactones. 
 
4. Conclusions 
 
 Sesquiterpene lactones are an important group of natural products 
obtained from many species of medicinal plants. Their structural diversity 
and diverse potential biological activities such as anticancer, anti-
inflammatory, anti-tumor, anti-malarial, antiviral, antibacterial, antifungal 
etc. have made further interest among the chemists to the drug discovery 
research. Although, the exact mechanism of action of SLs are not well    
known but it has been documented through the various published reports             
that the biological activity displayed by majority of sesquiterpene lactones                
is due to the presence of α-methylene-γ-lactones and α,β-unsaturated 
cyclopentenone ring. The present chapter deals an overview on the various 
kinds of biologically activity of structurally diverse sesquiterpene lactones 
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which may be useful for the chemists/pharmacologists working in the area of 
drug discovery of the relevant subject. 
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